Table 30. ACCF/AHA/AMA-PCPI 2011 HF Measurement Set
(continued)
Care
Setting
Level of
Measurement
Outpatient
• Individual
practitioner
Measure
Descriptiona
• Patient
self-care
educationb,c
Percentage of patients aged ≥18 y
with a diagnosis of HF who were
provided with self-care education on
≥3 elements of education during ≥1
visit(s) within a 12-mo period
• Beta-blocker
therapy
for LVSD
(outpatient
and inpatient
setting)
Percentage of patients aged ≥18 y
Inpatient
with a diagnosis of HF with a current and
or prior LVEF <40% who were
outpatient
prescribed beta-blocker therapy with
bisoprolol, carvedilol, or sustainedrelease metoprolol succinate either
within a 12-mo period when seen in
the outpatient setting or at hospital
discharge
• Individual
practitioner
• Facility
• ACE
inhibitor or
ARB therapy
for LVSD
(outpatient
and inpatient
setting)
Percentage of patients aged ≥18 y
Inpatient
with a diagnosis of HF with a current and
or prior LVEF <40% who were
outpatient
prescribed ACE inhibitor or ARB
therapy either within a 12-mo period
when seen in the outpatient setting
or at hospital discharge
• Individual
practitioner
• Facility
• Counseling
about ICD
implantation
for patients
with
LVSD on
combination
medical
therapyb,c
Percentage of patients aged ≥18 y
with a diagnosis of HF with current
LVEF ≤35% despite ACE inhibitor/
ARB and beta-blocker therapy for at
least 3 mo who were counseled about
ICD implantation as a treatment
option for the prophylaxis of sudden
death
• Individual
practitioner
• Postdischarge
appointment
for HF
patients
Percentage of patients, regardless of
Inpatient
age, discharged from an inpatient
facility to ambulatory care or home
health care with a principal discharge
diagnosis of HF for whom a followup appointment was scheduled and
documented including location, date
and time for a follow-up office visit,
or home health visit (as specified)
Outpatient
• Facility
Refer to the complete measures for comprehensive information, including measure exception.
Test measure designated for use in internal quality improvement programs only. These measures
are not appropriate for any other purpose (eg, pay for performance, physician ranking, or public
reporting programs).
c
New measure.
Adapted from Bonow RO, et al. Circulation. 2012;125:2382-2401.
a
b
53
